- Home
- STEW vs ATAI Comparison
STEW vs ATAI Comparison
Compare STEW & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEW | ATAI |
|---|---|---|
| Founded | 1972 | 2018 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | STEW | ATAI |
|---|---|---|
| Price | $18.33 | $3.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 84.5K | ★ 4.9M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | N/A | ★ $3,018,000.00 |
| Revenue This Year | N/A | $736.04 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.34 | ★ N/A |
| Revenue Growth | N/A | ★ 811.78 |
| 52 Week Low | $11.97 | $1.15 |
| 52 Week High | $14.94 | $6.75 |
Technical Indicators
Market Signals| Indicator | STEW | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 65.78 | 36.15 |
| Support Level | $17.60 | $3.60 |
| Resistance Level | $17.94 | $3.89 |
| Average True Range (ATR) | 0.20 | 0.25 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 93.84 | 26.79 |
Price Performance
Historical ComparisonAbout STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.